Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
22 February 2013Website:
http://www.kintara.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
regular market | Thu, 17 Oct 2024 20:00:01 GMTDividend
Analysts recommendations
Institutional Ownership
Included in screeners
KTRA Latest News
SAN DIEGO , Oct. 16, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. ("Kintara") (NASDAQ: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that its Board of Directors (the "Board") has approved a reverse stock split of Kintara's common stock at a ratio of 1-for-35. Kintara's common stock is expected to begin trading on a post-reverse stock split basis on the Nasdaq Capital Market on October 17, 2024, under the new name TuHURA Biosciences, Inc. and under the new symbol "HURA" following the anticipated closing of the merger (the "Merger") with TuHURA Biosciences, Inc. ("TuHURA"), with a new CUSIP number 898920 103.
SAN DIEGO , Oct. 16, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. ("Kintara") (NASDAQ: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced a correction to the press release previously issued by Kintara on October 16, 2024. Kintara announced today that its Board of Directors (the "Board") has approved a reverse stock split of Kintara's common stock at a ratio of 1-for-35.
SAN DIEGO , Oct. 8, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal fourth quarter ended June 30, 2024, and provided a corporate update. Recent Corporate Developments As previously disclosed, in April 2024 Kintara entered into a definitive merger agreement (the "Merger Agreement") with TuHURA Biosciences, Inc. ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, and Kayak Mergeco, Inc., Kintara's wholly-owned subsidiary, whereby Kayak Mergeco will merge with and into TuHURA with TuHURA surviving the merger and becoming Kintara's direct, wholly-owned subsidiary (the "Merger").
SAN DIEGO , Sept. 20, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced it adjourned the Special Meeting of Stockholders (the "Special Meeting") held on September 20, 2024.
Stockholders must vote by 11:59 p.m. ET on September 19, 2024 for their vote to count A "FOR" vote on Proposals 3 & 5 by holders of a majority of the voting power of Kintara's outstanding shares as of August 14, 2024 is required to allow for completion the proposed merger with TuHURA Biosciences SAN DIEGO , Sept.
Stockholders must vote by 11:59 p.m., Eastern Time, on September 19, 2024, for their vote to count SAN DIEGO , Sept.
Kintara (KTRA) inks a definitive merger agreement with TuHURA for an all-stock transaction. It is expected to close in the third quarter of 2024.
Kintara Therapeutics (NASDAQ: KTRA ) stock is rocketing higher on Wednesday after the biopharmaceutical company announced plans to merge with TuHURA Biosciences . Kintara Therapeutics and TuHURA Biosciences will use an all-stock transaction to combine the two companies.
SAN DIEGO , Aug. 9, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that its President and CEO, Robert E. Hoffman will present in the Emerging Growth Conference on Wednesday, August 9, 2023 at 12:00 pm ET.
Kintara (KTRA) receives a $2 million grant from the National Institutes of Health to develop its breast cancer treatment candidate, REM-001. The stock surges 41%.
What type of business is Kintara Therapeutics?
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.
What sector is Kintara Therapeutics in?
Kintara Therapeutics is in the Healthcare sector
What industry is Kintara Therapeutics in?
Kintara Therapeutics is in the Biotechnology industry
What country is Kintara Therapeutics from?
Kintara Therapeutics is headquartered in United States
When did Kintara Therapeutics go public?
Kintara Therapeutics initial public offering (IPO) was on 22 February 2013
What is Kintara Therapeutics website?
https://www.kintara.com
Is Kintara Therapeutics in the S&P 500?
No, Kintara Therapeutics is not included in the S&P 500 index
Is Kintara Therapeutics in the NASDAQ 100?
No, Kintara Therapeutics is not included in the NASDAQ 100 index
Is Kintara Therapeutics in the Dow Jones?
No, Kintara Therapeutics is not included in the Dow Jones index
When was Kintara Therapeutics the previous earnings report?
No data
When does Kintara Therapeutics earnings report?
Next earnings report date is not announced yet